In re Gabapentin Patent Litigation, MDL Docket No. 1384, Master Civil Action No. 00-2931, C.A. Nos. 00-CV-4168, 00-CV-4589, 00-CV-6073, 01-CV-0193, 01-CV-1537, and 01-CV-2194; U.S. District Court (DNJ); opinion by Hochberg, U.S.D.J.; filed August 27, 2009. DDS No. 53-7-5234 [27 pp.]
Plaintiffs, Warner-Lambert and others (referred to here in the singular), are the drug manufacturers and patent holders for gabapentin, a drug that is used to prevent and limit epileptic seizures. Gabapentin has been marketed under the tradename Neurontin. Defendants are generic drug manufacturers seeking to market generic versions of Neurontin.
